Patents by Inventor Anne Marie Camp

Anne Marie Camp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8420631
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: April 16, 2013
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams
  • Substituted [(5-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HTantagonists
    Patent number: 8314092
    Abstract: A dual H1/5-HT2A receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: November 20, 2012
    Assignee: Eli Lilly and Company
    Inventors: Anne Marie Camp, Peter Thaddeus Gallagher, Andrew James Ledgard, Adam Jan Sanderson, David Andrew Coates
  • SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS
    Publication number: 20120202797
    Abstract: A dual H1/5-HT2A receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: January 25, 2012
    Publication date: August 9, 2012
    Applicant: Eli Lilly and Company
    Inventors: Anne Marie CAMP, Peter Thaddeus GALLAGHER, Andrew James LEDGARD, Adam Jan SANDERSON, David Andrew COATES
  • 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists
    Patent number: 8202873
    Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently —C(H)? or —N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R1-4 are as defined herein.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: June 19, 2012
    Assignee: Eli Lilly and Company
    Inventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
  • 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 7981882
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: July 19, 2011
    Assignee: Eli Lilly and Company
    Inventors: Karin Briner, Anne Marie Camp, Alan Cornell, Michael Philip Mazanetz, Roger Ryan Rothhaar, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang
  • 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS
    Publication number: 20100120785
    Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)? or N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R14 are as defined herein.
    Type: Application
    Filed: May 7, 2008
    Publication date: May 13, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
  • 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
    Publication number: 20080214520
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.
    Type: Application
    Filed: September 1, 2006
    Publication date: September 4, 2008
    Inventors: Karin Briner, Anne Marie Camp, Alan Cornell, Michael Philip Mazanetz, Roger Ryan Rothhaar, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang
  • 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists
    Publication number: 20080207897
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.
    Type: Application
    Filed: September 1, 2006
    Publication date: August 28, 2008
    Inventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams